Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

PDF) Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC

Biology drives the discovery of bispecific antibodies as innovative therapeutics. - Abstract - Europe PMC

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Ida H Hiemstra's research works Genmab, Copenhagen and other places

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC

RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38

Crystal structure of CD38 in complex with daratumumab, a first-in-class anti -CD38 antibody drug for treating multiple myeloma - ScienceDirect

AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC

PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy

PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma